Genzyme changes Bioenvision bid

07/2/2007 | American City Business Journals

Genzyme Corp. says many Bioenvision shareholders failed to sell their stock to the Massachusetts biotech as part of the $345 million all-cash acquisition offer. Genzyme says it is changing its tender offer so it is not required to acquire at least half of the outstanding stock, and is extending the offer to buy stock until July 10.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations